Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amid US Cough Syrup Findings, Regulators Feel India Needs To Work On Perceptions But Also Make Improvements

Executive Summary

In wake of the furore caused by OTC cough syrups made by two small Indian companies, former and current US FDA and MHRA officials say quality-related issues are not specific to India. However, while image management needs some work, manufacturers in the country also need to make further improvements to ensure quality.

You may also be interested in...



Obituary: Ranjit Shahani, Ex-Novartis India Chief Who ‘Traveled Light’

Industry veteran and mentor to many, Ranjit Shahani steered Novartis India with seeming calm through a rocky phase when the Glivec patent case ruling didn't go the Swiss multinational's way - perhaps not unusual for someone who had seen the ebbs and flows of life closely when his parents moved to India as refugees from Pakistan.

India Sets Out Revised GMP Rules: Can It Weed Out Dodgy Players?

India’s revised GMP rules up the bar and lay out specifics for pharmaceutical quality systems, handling of product complaints and supplier audits, among other areas. While risk-based inspections are already being deployed, it will take unflinching enforcement to separate the wheat from the chaff across 10,000 manufacturing sites in the country.

From Supply Chain To Value Chain: OPPI’s Matai On Moving ‘Up’ Amidst Winds Of Policy Change In India

Incoming director general of the Organisation of Pharmaceutical Producers of India discusses the evolving policy and regulatory landscape in India in areas such as R&D and quality. Stricter adherence to ethical marketing practices could be focus in the coming year, Anil Matai adds.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147891

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel